SCHEMBL21633034

SCHEMBL21633034

CNC(=O)OCCC(Oc1ccccc1NC(=O)CN1CCC(c2cccc(O)c2)CC1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 6/20 0.49
▸ DRD2 P14416 3/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ PRCP P42785 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21632829 0.89 DRD4 (0.51) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL21633032 0.85 DRD4 (0.49) DRD4DRD2DRD3KDM4EALDH1A1
SCHEMBL21632814 0.83 PRCP (0.49) DRD4DRD2DRD3L3MBTL1PRCP
SCHEMBL21061257 0.78 ALDH1A1 (0.41) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL21633140 0.77 DRD2 (0.47) DRD4DRD2DRD3KMT2ACYP2D6
SCHEMBL21061282 0.75 SLC6A2 (0.42) DRD3ALDH1A1KMT2ACYP2D6CYP2C19
SCHEMBL21051933 0.73 GAA (0.40) DRD3ALDH1A1KMT2ACYP2D6CYP2C19
SCHEMBL21632846 0.73 MEN1 (0.52) KMT2AMEN1
SCHEMBL21658581 0.72 DRD2 (0.51) DRD4DRD2DRD3KMT2ACYP2D6
SCHEMBL21632816 0.72 ACHE (0.56) DRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020021021-A1 ORTHO SUBSTITUTED PHENOXYPROPYLAMINO AND BENZYLOXYPROPYLAMINO DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-01-30 — — WO disclosed
Send feedback